Jaguar Health announces issuance of patent for CDD treament methods

Napo Pharmaceuticals announced that the United States Patent and Trademark Office on January 2, 2024 issued a new U.S. patent to Napo for methods for treating congenital diarrheal disorders in patients with an inhibitor of chloride-ion transport such as crofelemer, Napo’s novel plant-based prescription drug. Jaguar is supporting investigator-initiated and investigator IND proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease – an ultrarare CDD – and short bowel syndrome in the US, European Union, and Middle East/North Africa regions, with results expected in 2024. In accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for MVID or SBS for these debilitating conditions.